The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients

Por Frary, Evan C., Gad, Dorte, Bastholt, Lars, Hess, Søren
Publicado no EJNMMI Res (2016)

A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer

Por Nygaard, Birte, Bastholt, Lars, Bennedbæk, Finn Noe, Klausen, Tobias Wirenfeldt, Bentzen, Jens
Publicado em 2013

Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy

Por Tolstrup, Lærke K., Bastholt, Lars, Zwisler, Ann-Dorthe, Dieperink, Karin B., Pappot, Helle
Publicado no J Patient Rep Outcomes (2019)

Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients’ and Clinicians’ Experiences

Por Tolstrup, Lærke K, Pappot, Helle, Bastholt, Lars, Zwisler, Ann-Dorthe, Dieperink, Karin B
Publicado no J Med Internet Res (2020)

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma

Por Soerensen, Anne Vest, Ellebaek, Eva, Bastholt, Lars, Schmidt, Henrik, Donia, Marco, Svane, Inge Marie
Publicado no Cancers (Basel) (2020)

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

Por Kverneland, Anders H., Enevold, Christian, Donia, Marco, Bastholt, Lars, Svane, Inge Marie, Nielsen, Claus H.
Publicado no Oncoimmunology (2018)

Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form

Por Tolstrup, Lærke K., Pappot, Helle, Zangger, Graziella, Bastholt, Lars, Zwisler, Ann-Dorthe, Dieperink, Karin B.
Publicado no Health Qual Life Outcomes (2018)

The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial

Por Tolstrup, Lærke K., Bastholt, Lars, Dieperink, Karin B., Möller, Sören, Zwisler, Ann-Dorthe, Pappot, Helle
Publicado no J Patient Rep Outcomes (2020)

Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid Tissue

Por Folkestad, Lars, Brandt, Frans, Brix, Thomas, Vogsen, Marianne, Bastholt, Lars, Grupe, Peter, Krogh Petersen, Jeanette, Hegedüs, Laszlo
Publicado no Eur Thyroid J (2017)

Large Discrepancy in the Results of Sensitive Measurements of Thyroglobulin Antibodies in the Follow-Up on Thyroid Cancer: A Diagnostic Dilemma

Por Nygaard, Birte, Bentzen, Jens, Laurberg, Peter, Pedersen, Susanne Møller, Bastholt, Lars, Handberg, Aase, Rytter, Carsten, Godballe, Christian, Faber, Jens
Publicado em 2012

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

Por Iversen, Trine Zeeberg, Brimnes, Marie Klinge, Nikolajsen, Kirsten, Andersen, Rikke Sick, Hadrup, Sine Reker, Andersen, Mads Hald, Bastholt, Lars, Svane, Inge Marie
Publicado em 2013

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Por Kirkwood, John M., Bastholt, Lars, Robert, Caroline, Sosman, Jeff, Larkin, James, Hersey, Peter, Middleton, Mark, Cantarini, Mireille, Zazulina, Victoria, Kemsley, Karin, Dummer, Reinhard
Publicado em 2011

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

Por Kreissl, Michael C., Bastholt, Lars, Elisei, Rossella, Haddad, Robert, Hauch, Ole, Jarząb, Barbara, Robinson, Bruce, Colzani, Raffaella, Foster, Meredith, Weiss, Richard, Schlumberger, Martin
Publicado no J Clin Oncol (2020)

Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer

Por Bastholt, Lars, Kreissl, Michael C., Führer, Dagmar, Maia, Ana L., Locati, Laura D., Maciel, Léa, Wu, Yi, Heller, Kevin N., Webster, Alan, Elisei, Rossella
Publicado no Eur Thyroid J (2016)

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Por Hamid, Omid, Schmidt, Henrik, Nissan, Aviram, Ridolfi, Laura, Aamdal, Steinar, Hansson, Johan, Guida, Michele, Hyams, David M, Gómez, Henry, Bastholt, Lars, Chasalow, Scott D, Berman, David
Publicado em 2011

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Por Ascierto, Paolo A., Bastholt, Lars, Ferrucci, Pier F., Hansson, Johan, Márquez Rodas, Iván, Payne, Miranda, Robert, Caroline, Thomas, Luc, Utikal, Jochen S., Wolter, Pascal, Kudlac, Amber, Tuson, Harriet, McKendrick, Jan
Publicado no Melanoma Res (2018)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

Por Bol, Kalijn Fredrike, Ellebaek, Eva, Hoejberg, Lise, Bagger, Mette Marie, Larsen, Mathilde Skaarup, Klausen, Tobias Wirenfeldt, Køhler, Ulrich Heide, Schmidt, Henrik, Bastholt, Lars, Kiilgaard, Jens Folke, Donia, Marco, Svane, Inge Marie
Publicado no Cancers (Basel) (2019)

Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial

Por Brose, Marcia S, Nutting, Christopher M, Jarzab, Barbara, Elisei, Rossella, Siena, Salvatore, Bastholt, Lars, de la Fouchardiere, Christelle, Pacini, Furio, Paschke, Ralf, KeeShong, Young, Sherman, Steven I, Smit, Johannes WA, Chung, John, Kappeler, Christian, Pena, Carol, Molnár, István, Schlumberger, Martin J
Publicado no Lancet (2014)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Por Ascierto, Paolo Antonio, Del Vecchio, Michele, Mackiewicz, Andrzej, Robert, Caroline, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Svane, Inge Marie, McNeil, Catriona, Rutkowski, Piotr, Loquai, Carmen, Mortier, Laurent, Hamid, Omid, Bastholt, Lars, Dreno, Brigitte, Schadendorf, Dirk, Garbe, Claus, Nyakas, Marta, Grob, Jean-Jacques, Thomas, Luc, Liszkay, Gabriella, Smylie, Michael, Hoeller, Christoph, Ferraresi, Virginia, Grange, Florent, Gutzmer, Ralf, Pikiel, Joanna, Hosein, Fareeda, Simsek, Burcin, Maio, Michele
Publicado no J Immunother Cancer (2020)

Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

Por Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D., Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier Francesco, Hill, Andrew, Wagstaff, John, Carlino, Matteo S., Haanen, John B., Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A., Ascierto, Paolo A., Long, Georgina V., Callahan, Margaret K., Postow, Michael A., Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M., Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D.
Publicado no N Engl J Med (2015)